- new drug development
- ovarian cancer
- drug resistance
Professor Stan Kaye was the Head of the Drug Development Unit at The Royal Marsden and The Institute of Cancer Research (ICR) until Professor Johann de Bono succeeded him in this post in 2012. He was also Head of the Gynaecology Unit at The Royal Marsden.
He was responsible for developing one of the world’s largest Phase I units, incorporating ten inpatient and five outpatient beds, over 80 staff and over 30 current new drug trials. Between 250 and 300 patients per year now enter Phase I trials in the Drug Development Unit.
Professor Kaye is now BRC Senior Fellow/RM Partners Research Director, with responsibilities for overseeing all clinical research across RM Partners which covers the geography of North West and South West London
Professor Kaye joined The Royal Marsden in September 2000 after 20 years in Glasgow (15 years of which were spent as Head of Medical Oncology at the university there). He qualified in medicine in 1972 in London, and completed training in medicine and oncology in London and Australia.
His major interests, apart from new drug development, are in ovarian cancer and drug resistance. Until recently he shared responsibility with Professor Martin Gore for the care of patients with gynaecological cancer at The Royal Marsden; in 2011 Dr Susana Banerjee joined the consultant team.
The author of over 350 peer-reviewed papers, he sits on the editorial boards of 12 cancer journals and has held various national and international responsibilities, most notably in Cancer Research UK (the world’s largest cancer charity) for which he previously chaired the Clinical and Translational Research Committee. In 2012 he was part of the ICR/Royal Marsden team awarded the American Association for Cancer Research Team Science Award.